Abstract:Introduction: The standard treatment for preventing rejection in vascularized composite allotransplantation (VCA) currently relies on systemic immunosuppression, which exposes the host to well-known side effects. Locally administered immunosuppression strategies have shown promising results to bypass this hurdle. Nevertheless, their progress has been slow, partially attributed to a limited understanding of the essential mechanisms underlying graft rejection. Recent discoveries highlight the crucial involvement of innate immune components, such as neutrophil extracellular traps (NETs), in organ transplantation. Here we aimed to prolong graft survival through a tacrolimus-based drug delivery system and to understand the role of NETs in VCA graft rejection. Methods: To prevent off-target toxicity and promote graft survival, we tested a locally administered tacrolimus-loaded on-demand drug delivery system (TGMS-TAC) in a multiple MHC-mismatched porcine VCA model. Off-target toxicity was assessed in tissue and blood. Graft rejection was evaluated macroscopically while the complement system, T cells, neutrophils and NETs were analyzed in graft tissues by immunofluorescence and/or western blot. Plasmatic levels of inflammatory cytokines were measured using a Luminex magnetic-bead porcine panel, and NETs were measured in plasma and tissue using DNA-MPO ELISA. Lastly, to evaluate the effect of tacrolimus on NET formation, NETs were induced in-vitro in porcine and human peripheral neutrophils following incubation with tacrolimus. Results: Repeated intra-graft administrations of TGMS-TAC minimized systemic toxicity and prolonged graft survival. Nevertheless, signs of rejection were observed at endpoint. Systemically, there were no increases in cytokine levels, complement anaphylatoxins, T-cell subpopulations, or neutrophils during rejection. Yet, tissue analysis showed local infiltration of T cells and neutrophils, together with neutrophil extracellular traps (NETs) in rejected grafts. Interestingly, intra-graft administration of tacrolimus contributed to a reduction in both T-cellular infiltration and NETs. In fact, in-vitro NETosis assessment showed a 62–84% reduction in NETs after stimulated neutrophils were treated with tacrolimus. Conclusion: Our data indicate that the proposed local delivery of immunosuppression avoids off-target toxicity while prolonging graft survival in a multiple MHC-mismatch VCA model. Furthermore, NETs are found to play a role in graft rejection and could therefore be a potential innovative therapeutic target.

Limited Efficacy of Rapamycin Monotherapy in Vascularized Composite Allotransplantation.

Tacrolimus before CTLA4Ig and rapamycin promotes vascularized composite allograft survival in MGH miniature swine

Rap1 Deficiency-Provoked Paracrine Dysfunction Impairs Immunosuppressive Potency of Mesenchymal Stem Cells in Allograft Rejection of Heart Transplantation

Rapamycin in Combination with Donor-Specific CD4+CD25+Treg Cells Amplified in Vitro Might Be Realize the Immune Tolerance in Clinical Organ Transplantation

Utility of IL-2 Complexes in Promoting the Survival of Murine Orthotopic Forelimb Vascularized Composite Allografts

A Combination of Anergic Cells' Adoptive Transfer and Rapamycin Therapy Prolongs Cardiac Allograft Survival in Mice

Robustness Testing of Mesenchymal Stem Cell Monotherapy Following Vascularized Composite Allotransplantation.

[Effect of Rapamycin on CD4(+) CD25(+) Regulatory T Cells in Allo-Transplantation Tolerance Model].

Topical Tacrolimus and Mycophenolic Acid Therapy Synergizes with Low Dose Systemic Immunosuppression to Sustain Vascularized Composite Allograft Survival

Immunomodulation of T Cell-Mediated Alloimmunity by Proximity to Endothelial Cells under the Mammalian Target of Rapamycin Blockade.

Graft-implanted, enzyme responsive, tacrolimus-eluting hydrogel enables long-term survival of orthotopic porcine limb vascularized composite allografts: A proof of concept study

Immunosuppression with a Combination of Triptolide and Cyclosporin A in Rat Vascularized Groin Flap Allotransplantation

Rapamycin Combined with Donor Immature Dendritic Cells Promotes Liver Allograft Survival in Association with CD4+CD25+Foxp3+ Regulatory T Cell Expansion

A local drug delivery system prolongs graft survival by dampening T cell infiltration and neutrophil extracellular trap formation in vascularized composite allografts

Rapamycin treated tol-dendritic cells derived from BM-MSCs reversed graft rejection in a rat liver transplantation model by inducing CD8+CD45RC-Treg

PD-L1 Cellular Nanovesicles Carrying Rapamycin Inhibit Alloimmune Responses in Transplantation.

Tacrolimus-loaded Drug Delivery Systems in Vascularized Composite Allotransplantation: Lessons and Opportunities for Local Immunosuppression

Ex-vivo Treatment of Allografts Using Adipose-Derived Stem Cells Induced Prolonged Rejection-Free Survival in an Allogenic Hind-Limb Transplantation Model

Pretreatment of Rapamycin Before Allogenic Corneal Transplant Promotes Graft Survival Through Increasing CD4(+)CD25(+)Foxp3(+) Regulatory T Cells.

Combined Regime of Rapamycin and Cyclosporine in the Prevention of Acute Rejection in Renal Allograft Recipients

Experimental study on inhibiting the keratoplasty immunologic rejection in rat by rapamycin